Effectiveness of Shortened Treatment Regimen for Hepatitis C Assessed

Share this content:
These promising results encourage the use of shorter treatment regimens, which have the potential to significantly reduce the cost of treatment.
These promising results encourage the use of shorter treatment regimens, which have the potential to significantly reduce the cost of treatment.

Treatment of chronic hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks may be equally as effective at achieving remission as longer-term (12-week) treatment, according to research recently published in the Journal of Hepatology.

Researchers compared several cohorts of patients registered in the German National  Hepatitis C Registry who had previously received either 8 or 12 weeks of oral LDV/SOF: Intention-to-Treat Group 1 (ITT1, the safety population), who had received either 8 weeks (n=968) or 12 weeks (n=1,415) of oral LDV/SOF; Intention-to-Treat Group 2 (ITT2, the effectiveness population) either 8 weeks (n=877) or 12 weeks (n=1,275) of oral LDV/SOF and also completed follow-up; and the per protocol analysis group (PP,  total N=2066; n=835 for 8-week treatment, n=1231 for 12-week treatment).

More than 84% (2,034/2,404) of the safety population (ITT1) and 98% (2,029/2,066) of the per protocol (PP) population achieved sustained HCV virological response at week 12.

The researchers identified high cure rates for noncirrhotic patients receiving 8-week treatment with oral LCV/SOF alone (98.3%) and their 12-week counterparts (98.1%) in the PP analysis group. For cirrhotic patients, the rates were lower, with 90.5% achieving remission but relapse occurred more frequently (9.5% vs 1.2%) compared with noncirrhotic patients.

The research team found that following the inclusion criteria laid out in the European Summary of Product Characteristics for 8-week oral LDV/SOF achieved the best results; these criteria included patients who were treatment naive and noncirrhotic, with HCV genotype 1.

These findings indicate that 8-week treatment for patients matching these criteria is effective and can both decrease costs and potentially increase adherence compared with 12-week treatment.

Reference

Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C [published online November 11, 2017]. J Hepatol. doi:10.1016/j.jhep.2017.11.009

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters